Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis

Naber, Kurt G.; Roscher, K.; Botto, H; Schaefer, V.

doi:10.1016/j.ijantimicag.2008.03.014

Cited by 49 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…hronic bacterial prostatitis (CBP) is a troublesome disease, showing an overall clinical and microbiological response rate to fluoroquinolones, the antibiotics of choice, of only 60% (1)(2)(3)(4). In CBP caused by Escherichia coli, the reported resistance rates are 11% to ciprofloxacin and 20% to norfloxacin (5).…”

mentioning

confidence: 99%

“…In CBP caused by Escherichia coli, the reported resistance rates are 11% to ciprofloxacin and 20% to norfloxacin (5). Co-trimoxazole is an alternative antibiotic option, but its cure rates are lower than those of other drugs (1,4). The resistance rate to co-trimoxazole is high in patients with urinary tract infections (UTI) (around 34% in Spain) (6), and reported resistance in E. coli CBP is 24% (5).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

Los‐Arcos

Pigrau

Rodríguez-Pardo

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

This is a retrospective study of 15 difficult-to-treat (i.e., exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks. After a median follow-up of 20 months, 7 patients (47%) had a clinical response, and 8 patients (53%) had persistent microbiological eradication; 4/5 patients with MDRE isolates achieved eradication. There were no side effects. Fosfomycin-tromethamine is a possible alternative therapy for chronic bacterial prostatitis. Chronic bacterial prostatitis (CBP) is a troublesome disease, showing an overall clinical and microbiological response rate to fluoroquinolones, the antibiotics of choice, of only 60% (1-4). In CBP caused by Escherichia coli, the reported resistance rates are 11% to ciprofloxacin and 20% to norfloxacin (5). Co-trimoxazole is an alternative antibiotic option, but its cure rates are lower than those of other drugs (1, 4). The resistance rate to co-trimoxazole is high in patients with urinary tract infections (UTI) (around 34% in Spain) (6), and reported resistance in E. coli CBP is 24% (5). Other antibiotics are usually ineffective due to poor prostatic penetration; hence, there may be no effective antibiotic therapy for some patients (1).Fosfomycin-tromethamine (FT) has broad-spectrum antimicrobial activity and is useful for treating lower UTI caused by extended-spectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae (7-10). Mean fosfomycin levels in the uninflamed peripheral prostate region after 3 g of FT were found to be Ͼ4 g/g of tissue in 70% of patients (11). This value is higher than the MIC breakpoint of many uropathogens. In addition, FT proved useful in 2 cases of multidrug-resistant Enterobacteriaceae (MDRE) prostatitis (12 In this retrospective study, we assessed the efficacy of FT as an alternative therapy for patients with difficult-to-treat CBP. The inclusion criteria were a diagnosis of CBP, failure of prolonged antibiotic therapy, and no possibility of fluoroquinolone or cotrimoxazole use due to resistance, failure, or side effects (Fig. 1). All patients had been treated and followed up in our UTI outpatient clinic (January 2010 to July 2014) by one of the authors (C.P.). The study was approved by the hospital ethics committee and Spanish Drug Agency (approval VDH-FOS-2014-01).A diagnosis of CBP was established when all 4 criteria were met: (i) history of CBP, defined as Ն1 previous symptomatic episode of bacterial prostatitis of Ն4 weeks duration or Ն2 episodes of any duration in the preceding 12 months; (ii) current symptoms of prostatitis; (iii) absence of genitourinary abnormalities on Ն1 urologic ultrasound assessment; and (iv) current laboratory evidence of infection, including positive Meares-Stamey test result (14), positive semen culture, or Ն2 positive urine cultures with the same microorganism performed Ն1 month apart, in which ...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

Los‐Arcos

Pigrau

Rodríguez-Pardo

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…These are highly desirable properties in the treatment of persisting and recurrent infections such as CBP, since they create a hostile milieu for commonly involved bacteria [44]. Notably, Giannarini et al [25] showed that prulifloxacin was microbiologically and clinically equivalent to levofloxacin, a reference drug for CBP [45]. This study also found a trend towards lower recurrence rates with prulifloxacin after 6 months.…”

Section: Page 13 Of 33mentioning

confidence: 70%

Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections

Rafailidis

Polyzos

Sgouros

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

To cite this version:Petros I. Rafailidis, Konstantinos A. Polyzos, Konstantinos Sgouros, Matthew E. Falagas.Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.International Journal of Antimicrobial Agents, Elsevier, 2011, 37 (4) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In summary, prulifloxacin appears to be a promising agent for the treatment of bacterial prostatitis and traveller's diarrhoea.

show abstract

“…Some infectious diseases such as chronic bacterial prostatitis, lower respiratory tract infections, urinary tract infections and H. pylori infection could be successfully cured by LEV [1][2][3]. The great potency of LEV encouraged several pharmaceutical industries to produce many brands of LEV.…”

Section: Introductionmentioning

confidence: 99%

A Rapid and Simple High-Performance Liquid Chromatographic Method for Determination of Levofloxacin in Human Plasma

et al. 2017

View full text Add to dashboard Cite

show abstract

Oral levofloxacin 500mg once daily in the treatment of chronic bacterial prostatitis

Cited by 49 publications

References 19 publications

Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections

A Rapid and Simple High-Performance Liquid Chromatographic Method for Determination of Levofloxacin in Human Plasma

Contact Info

Product

Resources

About